Medindia

X

MDS Announces Special Meeting of Shareholders and Record Date

Thursday, September 17, 2009 General News J E 4
Advertisement
TORONTO, Sept. 4 /PRNewswire-FirstCall/ - MDS Inc. (TSX: MDS; NYSE: MDZ), a leading provider of products and services to the global life-sciences markets, today announced that the Company has scheduled a Special Meeting of Shareholders to seek approval of the proposed sale of MDS Analytical Technologies to Danaher Corporation (NYSE: DHR). The meeting, which will commence at 4 p.m., will be held on October 20, 2009 at the Toronto Congress Centre.

The record date for the purpose of determining shareholders entitled to receive notice of, and to vote at, the Special Meeting is September 14, 2009.

The MDS Board of Directors believes the proposed sale of MDS Analytical Technologies to Danaher is in the best interests of the Company and its shareholders, and unanimously recommends that shareholders vote in favor of the sale.

MDS expects that a Management Proxy Circular for the shareholder meeting will be mailed to shareholders later this month and will be available at www.sedar.com, www.sec.gov/edgar.shtml and www.mdsinc.com. The Management Proxy Circular will provide important information about the proposed transaction as well as information related to voting procedures.

About MDS

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that our customers need for the development of drugs, and the diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS has more than 4,200 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.

SOURCE MDS Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Rib-X Pharmaceuticals, Inc. Appoints Tom Kassberg ...
S
Nurses and Retirement Security: A Looming Crisis?